Skip to main content
. 2022 May 10;63:103863. doi: 10.1016/j.msard.2022.103863

Fig. 1.

Fig. 1

Longitudinal serology response to SARS-CoV-2 mRNA vaccine of cladribine treated MS patients and HCs.Fig. 1 Serology response of HCs and cladribine tablets-treated MS patients following the 2nd and 3rd mRNA vaccine dose on logarithmic amplitude scale. 2–3 weeks (n = 31, 13,003±8893AU/ml vs n = 21, 11,135±12,029, p = 0.52), and 6 months (n = 46, 1153.0 ± 997.1 vs n = 36, 1088.0 ± 1072.0, p = 0.79) following the 2nd vaccine, and 1 month (n = 24, 26,394±11,335 vs n = 17, 15,598±11,313, p = 0.40) and 3–6 months (n = 8, 11,198±14,679 vs n = 5, 5234±4097, p = 0.40) following the 3rd vaccine. Data presented as mean±SD. Dotted line indicates positive threshold (≥50 AU/ml).